ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Impact of addition of immune checkpoint inhibitors to neoadjuvant chemotherapy in triple-negative breast cancer

Impact of addition of immune checkpoint inhibitors to neoadjuvant chemotherapy in triple-negative breast cancer

Study [reference]

Immunotherapy agent (target)		 Chemotherapy regimen Sub-group Immunotherapy Control (placebo) EFS results (IT versus control)
Number pCR* (%) Number pCR* (%)

KEYNOTE-522[1,2]

Pembrolizumab (PD-1)		 Weekly paclitaxel with carboplatin (weekly or every 3 weeks) for 12 weeks followed by doxorubicin or epirubicin and cyclophosphamide for 4 cycles All 784 65 390 51 At median follow-up of 39 months, 3-year EFS 84 versus 77% (HR 0.63, 95% CI 0.48-0.82)
PD-L1+ 656 69 317 55
PD-L1– 127 45 69 30

Impassion031[3]

Atezolizumab (PD-L1)		 Weekly nabpaclitaxel for 12 weeks followed by doxorubicin and cyclophosphamide for 4 cycles All 165 58 168 41 At approximately 20 months' median follow-up, EFS not reached (HR 0.76, 95% CI 0.4-1.44)
PD-L1+ 77 69 75 49
PD-L1– 88 48 93 34

NeoTRIPaPDL1[4]

Atezolizumab (PD-L1)		 Nabpaclitaxel and carboplatin days 1 and 8 every 21 days for 8 cycles All 138 49 142 44 Not reported
PD-L1+ 79 60 77 52
PD-L1– 59 34 65 35

GeparNUEVO[5,6]

Durvalumab (PD-L1)		 Weekly nabpaclitaxel for 12 weeks followed epirubicin and cyclophosphamide for 4 cycles All 88 53 86 44 At median follow-up of 42 months, 3-year iDFS 85 versus 77% (HR 0.54, 95% CI 0.27-1.09)
PD-L1+ 69 58 69 51
PD-L1– 11 44 9 18
WindowΔ 59 61 58 41

IT: immunotherapy; pCR: pathologic complete response; PD-1: programmed cell death protein 1; EFS: event-free survival; PD-L1: programmed cell death ligand 1; HR: hazard ratio; iDFS: invasive disease-free survival.

* pCR: ypT0/isN0.

¶ The pCR values listed for KEYNOTE-522 comes from the initial presentation of results for the first 602 patients. When results for all patients were available, final pCR rates were 63 and 56% for pembrolizumab and placebo, respectively.

Δ The first 117 patients treated on GeparNeuvo received a single dose of either durvalumab or placebo two weeks before starting neoadjuvant chemotherapy with the same agent; this was omitted after the study's independent data monitoring committee expressed concern about the delay in the start of chemotherapy; another 57 patients were subsequently treated without this "window" treatment.
References:
  1. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020; 382:810.
  2. Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 2022; 386:556.
  3. Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): A randomised, double-blind, phase 3 trial. Lancet 2020; 396:1090.
  4. Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol 2022; 33:534.
  5. Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 2019; 30:1279.
  6. Loibl S, Schneeweiss A, Huober J, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol 2022; 33:1149.
Graphic 129974 Version 3.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟